ZGNX Zogenix Inc.

48.67
+0.41  (+1%)
Previous Close 48.27
Open 48.5
Price To Book 8.6
Market Cap 2,154,100,492
Shares 44,254,761
Volume 34,710
Short Ratio
Av. Daily Volume 406,632
Stock charts supplied by TradingView

NewsSee all news

  1. Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting

    EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its

  2. JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

    Addition of FINTEPLA to stiripentol-inclusive regimens provided a 54% greater reduction in study patients' mean monthly convulsive seizure frequency compared to placeboA significantly greater proportion of study patients

  3. Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting

    EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its

  4. Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    EMERYVILLE, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a

  5. Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome

    EMERYVILLE, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 1Q 2020.
ZX008 - (Study 1601)
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Refusal to file Letter (RTF) issued April 8, 2019. NDA resubmitted with new PDUFA date under priority review March 25, 2020
FINTEPLA (ZX008)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting

    EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its

  2. JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

    Addition of FINTEPLA to stiripentol-inclusive regimens provided a 54% greater reduction in study patients' mean monthly convulsive seizure frequency compared to placeboA significantly greater proportion of study patients

  3. Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting

    EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its

  4. Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    EMERYVILLE, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a

  5. Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome

    EMERYVILLE, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has

  6. Zogenix to Present at Two Investor Conferences in November

    EMERYVILLE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and

  7. Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    Resubmitted NDA for FINTEPLA® for the treatment of Dravet syndromeEnrollment completed for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020Acquired Modis Therapeutics, Inc.;

  8. Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7

    EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the

  9. Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome

    Data have shown long-term, clinically meaningful convulsive seizure reduction (75.5%; p<0.001) in Dravet syndrome patients under 6 years old, as well as clinically meaningful and profound reduction in high-risk

  10. Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

    Safety and efficacy data from a global, retrospective Phase 2 study (RETRO) support potential for deoxynucleoside substrate enhancement therapy (SET) to treat TK2 deficiency, an often-fatal mitochondrial DNA depletion

  11. Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application

  12. Zogenix Completes Acquisition of Modis Therapeutics, Inc.

    EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition

  13. INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  14. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  15. Zogenix Announces Acquisition of Modis Therapeutics, Inc.

    Advances Zogenix's strategy to provide transformative therapies to patients and families living with serious rare diseasesAdds MT1621, a proprietary, late-stage investigational medicine targeting Thymidine Kinase 2